GlassScriptPhysician profile
Alison S Campbell
NPI 1205861754
$5,987.21
in general payments reported to CMS, 2019-2025
35 companies · $948 in 2025
The $948 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,051 · 2020: $307 · 2021: $212 · 2022: $328 · 2023: $988 · 2024: $1,153 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,088.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $816.62 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $661.46 | 2019-2025 | Jardiance |
| Amgen INC. | $612.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $512.17 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $420.84 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $391.52 | 2019-2025 | Wegovy, Saxenda |
| Mylan Specialty L.P. | $316.40 | 2023-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $302.80 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $300.85 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $258.88 | 2019-2022 | |
| Abbvie INC. | $222.93 | 2021-2025 | Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $180.50 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $173.77 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $162.19 | 2019-2022 | |
| Amarin Pharma, INC. | $130.45 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $71.96 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $58.07 | 2025 | |
| Phathom Pharmaceuticals, INC. | $43.39 | 2024-2025 | Voquezna |
| Sanofi Pasteur INC. | $37.61 | 2019 | |
| Axsome Therapeutics, INC. | $35.64 | 2024 | Auvelity |
| Arbor Pharmaceuticals, INC. | $27.87 | 2019 | |
| Irhythm Technologies, INC. | $25.69 | 2024 | Zio Monitor, Zio Xt Patch |
| Exact Sciences Corporation | $25.28 | 2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $24.09 | 2025 | Gvoke Hypopen |
| Seagen INC. | $21.36 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.93 | 2022 | |
| Circassia INC. | $18.09 | 2019 | |
| Medtronic, INC. | $16.77 | 2024 | Aquamantys(Tm) |
| Ironwood Pharmaceuticals, INC | $15.40 | 2023 | Linzess |
| Boston Scientific Corporation | $15.26 | 2025 | Enroute Transcarotid Neuroprotection System |
| Cipher Pharmaceuticals US LLC | $15.06 | 2025 | Spinosad, Natroba |
| Allergan, INC. | $14.92 | 2020 | |
| Dexcom, INC. | $13.23 | 2021 | |
| Eisai INC. | $11.77 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.